Serrapeptase is a proteolytic enzyme derived from the bacteria Serratia marcescens, originally found in the digestive system of silkworms. It works by breaking down proteins, fibrin, and biofilms, exhibiting anti-inflammatory, anti-edemic, fibrinolytic, and analgesic properties. Primarily used for reducing inflammation, swelling, pain, and breaking down scar tissue in various therapeutic applications.

Overview

Serrapeptase (serratiopeptidase, serralysin) is a metalloprotease enzyme belonging to the serralysin family, originally isolated from Serratia marcescens E15, a bacterium found in the intestine of the silkworm Bombyx mori. In nature, the silkworm uses this enzyme to dissolve its cocoon — a feat requiring the rapid degradation of a tough protein matrix — which illustrates the enzyme's remarkable proteolytic potency. Commercially, serrapeptase is produced through fermentation of Serratia species and is available as enteric-coated oral supplements (the enteric coating being essential to protect the enzyme from gastric acid degradation). It has been used extensively in Japan, Germany, and other European and Asian countries since the 1960s as an anti-inflammatory, analgesic, and mucolytic agent, often prescribed alongside antibiotics or used post-surgically.

Serrapeptase's anti-inflammatory mechanism is distinct from NSAIDs — rather than inhibiting prostaglandin synthesis, it works by degrading non-living tissue proteins, including fibrin (the structural protein of blood clots), bradykinin (a pain-mediating peptide), and other inflammatory mediators at the site of tissue injury. This proteolytic action reduces edema by breaking down fluid-trapping protein aggregates, thins mucus secretions by cleaving glycoproteins, and may enhance antibiotic penetration by degrading biofilms. Clinical studies have demonstrated efficacy in reducing post-surgical and post-traumatic swelling (particularly in oral and ENT surgery), decreasing pain and inflammation in conditions such as carpal tunnel syndrome and chronic sinusitis, and improving symptoms of breast engorgement in lactating women. A notable study showed significant reduction in cheek swelling after third molar extraction compared to placebo.

Despite its long clinical history, serrapeptase's evidence base has been criticized for relying on older, smaller trials with methodological limitations. More recent systematic reviews have called for larger, well-designed trials to definitively establish efficacy and optimal dosing. The bioavailability of oral serrapeptase in humans has also been questioned — as a large protein molecule (approximately 45-60 kDa), intestinal absorption is inherently limited, though proponents argue that sufficient quantities of active enzyme reach the circulation to produce clinical effects. Typical supplemental dosing ranges from 10,000-120,000 SPU (serrapeptase units) per day, taken on an empty stomach to prevent enzyme degradation by food proteins. Serrapeptase is often combined with other proteolytic enzymes including bromelain and nattokinase for comprehensive fibrinolytic and anti-inflammatory support. Caution is warranted in patients on anticoagulant therapy due to potential additive effects on fibrin degradation.

Mechanism of Action

Mechanism of Action

Serrapeptase (serratiopeptidase) is a metalloprotease originally isolated from Serratia marcescens bacteria found in the intestine of silkworms, where it dissolves the cocoon. As a 50-60 kDa zinc-containing endopeptidase, it has broad substrate specificity for proteins at inflammatory sites.

Proteolytic Anti-Inflammatory Mechanism

Unlike NSAIDs that inhibit COX enzymes, serrapeptase reduces inflammation through direct proteolysis of inflammatory mediators. It degrades bradykinin (the primary pain-producing kinin), cleaves immune complexes, and breaks down complement activation products (C3a, C5a). By reducing these mediators at the tissue level, it decreases vascular permeability, edema, and pain signaling. Clinical studies show reductions in post-surgical swelling comparable to NSAIDs.

Fibrinolytic and Scar Tissue Effects

Serrapeptase directly hydrolyzes fibrin through its serine protease activity and also converts plasminogen to plasmin, enhancing endogenous fibrinolysis. This dual action degrades pathological fibrin deposits including scar tissue, arterial fibrin plaques, and fibrinous adhesions. The enzyme preferentially targets dead or damaged tissue while sparing living tissue, likely because living cells have protease inhibitors (serpins) on their surface.

Biofilm Disruption

Bacterial biofilms are protected by an extracellular matrix of proteins, polysaccharides, and DNA. Serrapeptase degrades the protein scaffold of this matrix, destabilizing biofilm architecture. In vitro studies demonstrate enhanced antibiotic penetration and efficacy against Staphylococcus aureus and Pseudomonas aeruginosa biofilms when combined with serrapeptase. This is particularly relevant for chronic infections involving implanted medical devices.

Respiratory Mucolysis

In the respiratory tract, serrapeptase reduces sputum viscosity by cleaving the protein backbone of mucin glycoproteins. This improves mucociliary clearance and reduces airway obstruction in chronic bronchitis and sinusitis. The enzyme also reduces neutrophil elastase activity in airways, potentially protecting airway epithelium from protease-mediated damage.

Pharmacokinetic Considerations

Serrapeptase is enterically coated to survive gastric acid. After intestinal absorption, it binds to alpha-2-macroglobulin in plasma, which masks it from immune surveillance and protease inhibitors while maintaining enzymatic activity. This carrier protein delivers the active enzyme to sites of inflammation where vascular permeability is increased.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Serrapeptase (Serratiopeptidase)

Common Side Effects

• Gastrointestinal disturbance: nausea, diarrhea, stomach pain, and reduced appetite
• Skin reactions: dermatitis, pruritus, and rash (reported in post-marketing surveillance in Japan)
• Muscle and joint aches
• Mild cough (related to mucolytic effects and sputum mobilization)

Serious Adverse Effects

• Pneumonitis and lung injury: case reports from Japan describe eosinophilic pneumonia and drug-induced lung disease associated with serrapeptase
• Coagulopathy: serrapeptase has fibrinolytic and anti-inflammatory properties; at higher doses, it may impair normal blood clotting and increase bleeding risk, including epistaxis and prolonged wound bleeding
• Severe allergic reactions: urticaria, angioedema, and rare anaphylaxis reported in post-marketing surveillance
• Liver enzyme elevation: isolated cases of mild hepatotoxicity
• Stevens-Johnson syndrome: extremely rare but reported in Japanese pharmacovigilance data
• Efficacy concerns: Japan removed serrapeptase from its approved drug list in 2011 after re-evaluation found insufficient evidence of efficacy for its approved indications; safety was not the primary concern but the evidence base is notably thin

Contraindications

• Known allergy to serrapeptase or silkworm-derived proteins
• Active bleeding disorders or hemorrhagic conditions
• Concurrent anticoagulant or antiplatelet therapy without medical supervision
• Pre-surgical period (discontinue at least 2 weeks before planned surgery)
• Severe hepatic impairment

Drug Interactions

• Anticoagulants (warfarin, heparin, DOACs) and antiplatelets (aspirin, clopidogrel): additive bleeding risk due to fibrinolytic activity; INR monitoring essential with warfarin
• NSAIDs: combined anti-inflammatory and antiplatelet effects increase GI bleeding risk
• Antibiotics: some evidence that serrapeptase may enhance antibiotic penetration into biofilms and tissues; while potentially beneficial, this could alter antibiotic pharmacokinetics unpredictably
• Other proteolytic enzymes (nattokinase, bromelain, lumbrokinase): stacking fibrinolytic enzymes compounds bleeding risk significantly

Population-Specific Considerations

• Post-surgical patients: historically used in Japan and Europe for reducing post-operative swelling; evidence is weak and inconsistent; risk of post-surgical bleeding must be weighed
• Sinusitis/respiratory conditions: mucolytic properties may help thin secretions; modest evidence from older clinical trials
• Pregnancy / lactation: no safety data; avoid use
• Elderly: heightened bleeding risk, especially if on anticoagulants; use with caution
• Enteric coating: serrapeptase is destroyed by gastric acid; only enteric-coated formulations are bioavailable; non-enteric-coated products are essentially inactive

Pharmacokinetic Profile